( EuronextBrussels:THR )

News from ThromboGenics NV A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 07, 2013, 13:04 ET ThromboGenics Business Update

- JETREA® slowly continues to gain acceptance with the US retina community. - Company increasing US medical education...


Oct 22, 2013, 20:00 ET National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT), Including When Associated With Macular Hole

Final guidance confirms metamorphopsia, an early symptom of VMT, as severe and distressing, requiring early treatment - NICE final guidance...


Oct 21, 2013, 01:30 ET ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines,...


Aug 02, 2013, 01:30 ET Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines,...


May 16, 2013, 12:15 ET ThromboGenics Business Update

- JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million -...


Apr 11, 2013, 11:45 ET ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK

First EU JETREA® order triggers €45 million milestone payment from Alcon to ThromboGenics ThromboGenics NV (Euronext Brussels:...


Mar 18, 2013, 02:30 ET ThromboGenics Starts Trading as Part of the BEL20 Index Today

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


Mar 14, 2013, 13:48 ET ThromboGenics Announces Business Update and 2012 Full-Year Results

Transformational 2012 Delivers Euro 30 Million in Net Profit REGULATED INFORMATION ThromboGenics NV (Euronext Brussels: THR), an integrated...


Feb 28, 2013, 16:52 ET New Paper in Cell Highlights the Potential Role of TB-403 (Anti-PlGF) in the Treatment of Medulloblastoma, a Pediatric Brain Tumor

ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce today the publication of a...


Jan 04, 2013, 01:30 ET ThromboGenics Confirms JETREA® US Launch Date of Monday January 14th, 2013

JETREA® US Price Set at USD 3,950 per Vial ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused...


Nov 29, 2012, 10:29 ET ThromboGenics Lands Licensing Deal of the Year at SCRIP Awards 2012

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


Nov 08, 2012, 12:53 ET ThromboGenics NV - Business Update

Regulated Information Disclosure in accordance with the law of May 2, 2007 ThromboGenics NV (Euronext Brussels: THR), an integrated...


Oct 18, 2012, 01:35 ET U.S. FDA Approves ThromboGenics' JETREA® (Ocriplasmin) for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)

JETREA® is the first pharmacological agent approved for the treatment of symptomatic VMA Conference call scheduled today at 15.00 CET...


Aug 30, 2012, 11:45 ET ThromboGenics NV - Business Update

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a...


Aug 15, 2012, 17:06 ET ThromboGenics Announces Publication of New England Journal of Medicine Paper Entitled "Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes"

Paper highlights that ocriplasmin is superior to placebo in resolving VMT and closing macular holes in patients with Vitreomacular Adhesions...


Jul 26, 2012, 21:02 ET FDA Advisory Committee Recommends ThromboGenics' Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)

- ThromboGenics to hold conference call to discuss the panel recommendation ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical...


Jul 12, 2012, 13:38 ET ThromboGenics Transparency Declaration

ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that...


Jul 03, 2012, 02:18 ET ThromboGenics Announces FDA Accepts Filing and Grants Priority Review to Its Biologics License Application for Ocriplasmin Intravitreal Injection

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that...


Jun 22, 2012, 01:30 ET ThromboGenics to Benefit From Positive Ruling Regarding Patent Income Deduction

Effective tax rate to be reduced significantly ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing...


May 10, 2012, 11:55 ET ThromboGenics NV - Business Update

Regulated Information Disclosure in accordance with the law of May 2, 2007 ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical...


Apr 17, 2012, 01:30 ET ThromboGenics Resubmits BLA for Ocriplasmin With the FDA

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that...


Apr 13, 2012, 13:03 ET ThromboGenics NV: Transparency Declaration

ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that...


Mar 29, 2012, 09:36 ET ThromboGenics Completes Private Placement Raising €77.8 Million

ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today...


Mar 16, 2012, 02:15 ET ThromboGenics Enters into Commercialization Agreement for Ocriplasmin with Alcon Outside the United States

ThromboGenics to concentrate on realizing ocriplasmin's significant commercial potential in the U.S. - ThromboGenics to receive €75...


Mar 08, 2012, 11:40 ET ThromboGenics Announces Business Update and 2011 Full-Year Results

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a...